Eli Lilly (NY:LLY)

Animal health company Elanco (NYSE:ELAN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 12.2% year on year to $1.14 billion. Guidance for next quarter’s revenue was...

Topics Artificial Intelligence

Elanco (NYSE:ELAN) Surprises With Q4 CY2025 Sales

February 24, 2026

Via StockStory

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China ↗

February 24, 2026

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

Is Eli Lilly Stock Underperforming the S&P 500?

February 24, 2026

Via Barchart.com

Topics Stocks

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗

February 23, 2026

Is this the best way to cash in on the weight-loss gold rush?

Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.

Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗

February 23, 2026

Stock Market Today, Feb. 23: Nvidia Earnings Loom as Tariff Concerns Drive Dow 800 Points Lower ↗

Topics Stocks

February 23, 2026

AI jitters, tariff shock, and looming Nvidia results have investors fleeing growth for perceived safety, today, Feb. 23, 2026.

It's worth sticking with the stock through the hard times.

Topics Artificial Intelligence Government Stocks

1 Reason I'd Buy Veeva Systems Stock and Never Sell ↗

February 23, 2026

Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.

Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?

February 23, 2026

Via Barchart.com

Eli Lilly (LLY) Stock Is Up, What You Need To Know

February 23, 2026

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.8% in the afternoon session after a major competitor, Novo Nordisk, announced that its experimental obesity drug failed to show it...

Via StockStory

Topics Artificial Intelligence

The Great Reshoring: US Manufacturing Renaissance Hits High Gear Amid Tariff Volatility

February 23, 2026

WASHINGTON D.C. — In a dramatic shift of the global economic landscape, the United States is currently witnessing a massive "repatriation" of industrial capacity, commonly referred to as the US...

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

Topics Economy Government World Trade

February 23, 2026

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

Why Viking Therapeutics Stock Is Up More Than 9% Today ↗

February 23, 2026

Hedge Funds' Mag 7, Eli Lilly Buying Spree Sparks Massive ETF Accumulation In IVV, SPY, QQQ ↗

Which S&P500 stocks are moving on Monday? ↗

February 23, 2026

Via Chartmill

February 23, 2026

Hedge funds bet heavily on big tech, Eli Lilly, and others in Q4, driving flows into SPY, QQQ, as mega-cap stocks dominated portfolio allocations.

Via Benzinga

Topics ETFs

Novo Nordisk's Loss Is Eli Lilly's Gain ↗

February 23, 2026

Eli Lilly shares climb after Novo Nordisk trial miss. CagriSema trails tirzepatide in 84-week weight-loss study results.

Via Benzinga

Is Microsoft Down? Downdetector Reports Issues With Azure, Outlook, MSFT 365 ↗

February 23, 2026

Microsoft flagged that services that require Multi-Factor Authentication may return gateway timeout errors for users in the U.S.

Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).

Why Eli Lilly Stock Just Popped ↗

February 23, 2026

GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.

Why Novo Nordisk Stock Just Crashed ↗

February 23, 2026

Eli Lilly: The Weight‑Loss and Diabetes Powerhouse I'd Hold Through Any Market Crash ↗

February 23, 2026

The stock looks unstoppable.

High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026

Topics Artificial Intelligence Economy

February 23, 2026

As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the...

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

February 23, 2026

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated...

Eli Lilly Announces New Version Of Zepbound With A Month’s Worth Of Doses In KwikPen — How Much Will It Cost? ↗

Topics Earnings

Eli Lilly Unusual Options Activity For February 23 ↗

February 23, 2026

Via Benzinga

February 23, 2026

The new Zepbound KwikPen can be purchased by cash-paying customers through LillyDirect, Eli Lilly’s direct-to-customer website.

Novo's next-gen drug CagriSema didn't match weight loss from Eli Lilly's Zepbound.

Wondering what's happening in today's S&P500 pre-market session? ↗

February 23, 2026

Via Chartmill

Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound ↗

February 23, 2026

Via Investor's Business Daily

1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock ↗

February 23, 2026

Novo Nordisk investors get a second bite at the Ozempic apple.

Viking stock has plenty of room to run.

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗

February 23, 2026